Chest ACCP Education Calendar
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mehdi, S. A.
Right arrow Articles by Graziano, S. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mehdi, S. A.
Right arrow Articles by Graziano, S. L.
(Chest. 1998;114:1309-1315.)
© 1998 American College of Chest Physicians

Prognostic Significance of Lewis y Antigen in Resected Stage I and II Non-small Cell Lung Cancer

Syed A. Mehdi MD1; Arthur H. Tatum MD, PhD2; Nancy B. Newman MS1; Anna Imperato MD1; John Daucher 2; Leslie J. Kohman MD, FCCP3; and Stephen L. Graziano MD1

1 From the Department of Medicine, Veterans Affairs Medical Center and State University of New York-Health Science Center, Syracuse, NY 13210
2 From the Department of Pathology, Veterans Affairs Medical Center and State University of New York-Health Science Center, Syracuse, NY 13210
3 From the Department of Surgery, Veterans Affairs Medical Center and State University of New York-Health Science Center, Syracuse, NY 13210

Stephen L. Graziano, MD, Veterans Affairs Medical Center, 800 Irving Avenue, Syracuse, NY 13210

Background: The role of Lewis y (Ley) antigen expression has been studied extensively in predicting the outcome of various malignancies. We evaluated the expression of Ley and its relationship to survival, disease-free survival and other clinicopathologic variables in patients with stage I and II non-small cell lung cancer (NSCLC).

Objective: To investigate the prognostic significance of Ley antigen expression in a large group of well characterized patients with resected stage I and II NSCLC.

Patients: Two hundred and sixty patients with surgically resected stage I (n = 193) and II (n = 67) NSCLC with at least 5-year follow-up were identified.

Results: The median survival for patients with negative expression of Ley (< 50% of cells that were positive) was 46 months, whereas for those with positive expression of Ley (ge 50%), the median survival was 54 months (p = 0.99). The disease-free survival for patients with Ley(minus) expression was 39 months and 34 months for patients with Ley(+) expression (p = 0.3).

Conclusions: We found no relationship between loss of blood group antigen A and expression of Ley. No statistically significant difference was found in survival between positive and negative expression of Ley antigen in patients with resected stage I and II NSCLC.

Key Words: antigen A • blood group antigens • Lewis y antigen • non-small cell lung cancer • ploidy • prognosis

Submitted on January 5, 1998
Accepted on June 19, 1998






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American College of Chest Physicians.